TickerFacts.

Anbio Biotechnology (NNNN): EPS (Diluted)

Annual figures by period end, from SEC filings.

$0.15
Year ended 2025-12-31
-98.9%
3-year compound annual growth
$100112.002022-12-31: $100112.002023-12-31: $0.102024-12-31: $0.0562025-12-31: $0.15$0.15
2022-12-31 EPS (Diluted) (USD per share) 2025-12-31
Period endedEPS (Diluted)Change YoYSource filing
2025-12-31$0.15+162.5%2026-04-07, From 2025-01-01
2024-12-31$0.056-46.7%2026-04-07, From 2024-01-01
2023-12-31$0.10-100.0%2026-04-07, From 2023-01-01
2022-12-31$100112.00n/a2025-04-28, From 2022-01-01

EPS (Diluted) at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedEPS (Diluted)Change YoY
Anbio Biotechnology (NNNN)2025-12-31$0.15+162.5%
Aspira Women's Health Inc. (AWHL)2025-12-31-$0.37n/m
Biomerica Inc (BMRA)2026-05-31-$1.30n/m
Insight Molecular Diagnostics Inc. (IMDX)2025-12-31-$1.65n/m
Immucell Corp (ICCC)2025-12-31-$0.12n/m
Alpha Teknova, Inc. (TKNO)2025-12-31-$0.32n/m
Volitionrx Ltd (VNRX)2024-12-31-$0.31n/m
Celldex Therapeutics, Inc. (CLDX)2025-12-31-$3.90n/m
Intellia Therapeutics, Inc. (NTLA)2025-12-31-$3.81n/m

Compare NNNN, AWHL, BMRA, IMDX side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗